Document is current
Any future updates will be listed below
-
Authors
Esayas, Endashaw
Louie, William
Routledge, Isobel
Murphy, Maxwell
Demeke, Nigatu Negash
De Amaral, Faith
Aranda-Díaz, Andrés
Greenhouse, Bryan
Kassa, Fikregabrail Aberra
Nigusse, Tedros
Assefa, Muluken
Ashine, Temesgen
Getachew, Asefaw
Ntuku, Henry
Golassa, Lemu
Gadisa, Endalamaw
Bennett, Adam
Smith, Jennifer L.
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-003212)
National Institute of Allergy and Infectious Diseases (5K01AI153555)
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 14 November 2025
First Online: 26 November 2025
Declarations
:
: The authors declare no competing interests.
: Ethical approval for the study was obtained from the National Research Ethical Review Committee (NRERC), Addis Ababa, Ethiopia (reference number: 02/256/630/14), AHRI/ALERT Ethics Review Committee (protocol number: P0-08-22), Aklilu Lemma Institute of Pathobiology Institutional Research Ethics Review Committee (reference number: ALIPB IRERC/111/2015/23) and the WCG IRB approval (protocol number: 1769134-1; IRB tracking number: 20214694). Written informed consent was obtained from the parents and/or legal guardians of all participants under the age of 18. In addition, written assent was obtained from participants aged 12 to 17 years. For participants aged 18 years and older, informed consent was obtained directly from the individuals. Participation in the study was voluntary. All methods used in this study were performed in accordance with good laboratory practice guidelines and regulations. All cases testing positive for malaria by RDT at point of care were administered first-line treatment for uncomplicated malaria in line with national guidelines: artemisinin-based combination therapies (ACTs) for P. falciparum and chloroquine for P. vivax .
